2-Allyl-1-(6-(2-Hydroxypropan-2-Yl)Pyridin-2-Yl)-6-((4-(4-Methylpiperazin-1-Yl)Phenyl)Amino)-1H-Pyrazolo[3,4-D]Pyrimidin-3(2H)-One 2-烯丙基-1-(6-(2-羟基丙-2-基)吡啶-2-基)-6-(4-(4-甲基哌嗪-1-基)苯基氨基)-1H-吡唑并[3,4-D]嘧啶-3(2H)-酮
CAS 955365-80-7 MFCD055365807
化学结构图
SMILES: C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1
化学属性
| Mol. Formula | C27H32N8O2 |
|---|---|
| Mol. Weight | 500.59538 |
| Appearance | Yellow solid powder |
| Solubility | Soluble in DMSO, not in water |
别名和识别编码
| Chemical Name | 2-Allyl-1-(6-(2-Hydroxypropan-2-Yl)Pyridin-2-Yl)-6-((4-(4-Methylpiperazin-1-Yl)Phenyl)Amino)-1H-Pyrazolo[3,4-D]Pyrimidin-3(2H)-One |
|---|---|
| Chemical Name Translation | 2-烯丙基-1-(6-(2-羟基丙-2-基)吡啶-2-基)-6-(4-(4-甲基哌嗪-1-基)苯基氨基)-1H-吡唑并[3,4-D]嘧啶-3(2H)-酮 |
| PubChem Substance ID | 24856436 |
| InChI | InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31) |
| LabNetwork Molecule ID | LN01331009 |
| Synonym | 2-allyl-1-(6-(2-hydroxy-2-propanyl)-2-pyridinyl)-6-((4-(4-methyl-1-piperazinyl)phenyl)amino)-1,2-dihydro-3H-pyrazolo(3,4-d)pyrimidin-3-one 3H-pyrazolo(3,4-D)pyrimidin-3-one, 1,2-dihydro-1-(6-(1-hydroxy-1-methylethyl)-2-pyridinyl)-6-((4-(4-methyl-1-piperazinyl)phenyl)amino)-2-(2-propen-1-yl)- AZD 1775 AZD-1775 AZD1775 MK 1775 MK-1775 MK-1775; MK1775; MK 1775; AZD1775; AZD-1775; AZD 1775; adavosertib. MK1775 |
| Formula | C27H32N8O2 |
| IUPAC Name | 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one |
| InChIKey | BKWJAKQVGHWELA-UHFFFAOYSA-N |
| Canonical SMILES | O=C1N(CC=C)N(C2=NC(C(C)(O)C)=CC=C2)C3=NC(NC4=CC=C(N5CCN(C)CC5)C=C4)=NC=C31 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
产品应用
- MK-1775, also known as adavosertib, AZD-1775, is a WEE1 inhibitor, is also a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. MK-1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents.
